VCA
PACB icon

Verdence Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Verdence Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,415
Closed -$19.5K – 727
2025
Q4 		$19.5K Buy
+10,415
New +$20K ﹤0.01% 650

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Verdence Capital Advisors's PACB Position: Q1 2026 in Review

Verdence Capital Advisors sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 10,415 shares — an estimated $19.5K sold.

Verdence Capital Advisors first reported a position in PACB in Q4 2025 and held it in 1 quarter. The position peaked at $19.5K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Verdence Capital Advisors reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verdence Capital Advisors sold 10,415 Pacific Biosciences shares in Q1 2026, an estimated $19.5K.
  • Verdence Capital Advisors first reported a position in Pacific Biosciences in Q4 2025 and held it in 1 quarter.
  • Verdence Capital Advisors's Pacific Biosciences position peaked at $19.5K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.